Cargando…

A lncRNA prognostic signature associated with immune infiltration and tumour mutation burden in breast cancer

Current studies have shown that long non‐coding RNAs (lncRNAs) may serve as prognostic biomarkers in multiple cancers. Therefore, we postulated that expression patterns of multiple lncRNAs combined into a single signature could improve clinicopathological risk stratification and prediction of overal...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zijian, Mi, Mi, Li, Xiaoqian, Zheng, Xin, Wu, Gang, Zhang, Liling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687003/
https://www.ncbi.nlm.nih.gov/pubmed/32967061
http://dx.doi.org/10.1111/jcmm.15762
_version_ 1783613441798307840
author Liu, Zijian
Mi, Mi
Li, Xiaoqian
Zheng, Xin
Wu, Gang
Zhang, Liling
author_facet Liu, Zijian
Mi, Mi
Li, Xiaoqian
Zheng, Xin
Wu, Gang
Zhang, Liling
author_sort Liu, Zijian
collection PubMed
description Current studies have shown that long non‐coding RNAs (lncRNAs) may serve as prognostic biomarkers in multiple cancers. Therefore, we postulated that expression patterns of multiple lncRNAs combined into a single signature could improve clinicopathological risk stratification and prediction of overall survival rate for breast cancer patients. Two algorithms, Least Absolute Shrinkage and Selector Operation (LASSO) and Support Vector Machine‐Recursive Feature Elimination (SVM‐RFE), were used to select candidate lncRNAs. Univariate and multivariate Cox regression analyses were employed to construct a seven‐lncRNA signature for breast cancer. Stratified analysis revealed that the signature was significantly associated with multiple clinicopathological risk factors. For clinical use, we developed a nomogram model to predict overall survival and odds of death for breast cancer patients. Single‐sample gene set enrichment analysis (ssGSEA), CIBERSORT algorithm and ESTIMATE method were employed to assess the relative immune cell infiltrations of each sample. Differentially infiltration of immune cells and diverse tumour mutation burden (TMB) scores might give rise to the efficacy of lncRNA signature for predicting the overall survival of patients. Correlation analysis implied that LINC01215 was associated with multiple immune‐related signalling pathways. A seven‐lncRNA prognostic signature is a reliable tool to predict the prognosis of breast cancer patients.
format Online
Article
Text
id pubmed-7687003
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-76870032020-12-03 A lncRNA prognostic signature associated with immune infiltration and tumour mutation burden in breast cancer Liu, Zijian Mi, Mi Li, Xiaoqian Zheng, Xin Wu, Gang Zhang, Liling J Cell Mol Med Original Articles Current studies have shown that long non‐coding RNAs (lncRNAs) may serve as prognostic biomarkers in multiple cancers. Therefore, we postulated that expression patterns of multiple lncRNAs combined into a single signature could improve clinicopathological risk stratification and prediction of overall survival rate for breast cancer patients. Two algorithms, Least Absolute Shrinkage and Selector Operation (LASSO) and Support Vector Machine‐Recursive Feature Elimination (SVM‐RFE), were used to select candidate lncRNAs. Univariate and multivariate Cox regression analyses were employed to construct a seven‐lncRNA signature for breast cancer. Stratified analysis revealed that the signature was significantly associated with multiple clinicopathological risk factors. For clinical use, we developed a nomogram model to predict overall survival and odds of death for breast cancer patients. Single‐sample gene set enrichment analysis (ssGSEA), CIBERSORT algorithm and ESTIMATE method were employed to assess the relative immune cell infiltrations of each sample. Differentially infiltration of immune cells and diverse tumour mutation burden (TMB) scores might give rise to the efficacy of lncRNA signature for predicting the overall survival of patients. Correlation analysis implied that LINC01215 was associated with multiple immune‐related signalling pathways. A seven‐lncRNA prognostic signature is a reliable tool to predict the prognosis of breast cancer patients. John Wiley and Sons Inc. 2020-09-23 2020-11 /pmc/articles/PMC7687003/ /pubmed/32967061 http://dx.doi.org/10.1111/jcmm.15762 Text en © 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Liu, Zijian
Mi, Mi
Li, Xiaoqian
Zheng, Xin
Wu, Gang
Zhang, Liling
A lncRNA prognostic signature associated with immune infiltration and tumour mutation burden in breast cancer
title A lncRNA prognostic signature associated with immune infiltration and tumour mutation burden in breast cancer
title_full A lncRNA prognostic signature associated with immune infiltration and tumour mutation burden in breast cancer
title_fullStr A lncRNA prognostic signature associated with immune infiltration and tumour mutation burden in breast cancer
title_full_unstemmed A lncRNA prognostic signature associated with immune infiltration and tumour mutation burden in breast cancer
title_short A lncRNA prognostic signature associated with immune infiltration and tumour mutation burden in breast cancer
title_sort lncrna prognostic signature associated with immune infiltration and tumour mutation burden in breast cancer
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687003/
https://www.ncbi.nlm.nih.gov/pubmed/32967061
http://dx.doi.org/10.1111/jcmm.15762
work_keys_str_mv AT liuzijian alncrnaprognosticsignatureassociatedwithimmuneinfiltrationandtumourmutationburdeninbreastcancer
AT mimi alncrnaprognosticsignatureassociatedwithimmuneinfiltrationandtumourmutationburdeninbreastcancer
AT lixiaoqian alncrnaprognosticsignatureassociatedwithimmuneinfiltrationandtumourmutationburdeninbreastcancer
AT zhengxin alncrnaprognosticsignatureassociatedwithimmuneinfiltrationandtumourmutationburdeninbreastcancer
AT wugang alncrnaprognosticsignatureassociatedwithimmuneinfiltrationandtumourmutationburdeninbreastcancer
AT zhangliling alncrnaprognosticsignatureassociatedwithimmuneinfiltrationandtumourmutationburdeninbreastcancer
AT liuzijian lncrnaprognosticsignatureassociatedwithimmuneinfiltrationandtumourmutationburdeninbreastcancer
AT mimi lncrnaprognosticsignatureassociatedwithimmuneinfiltrationandtumourmutationburdeninbreastcancer
AT lixiaoqian lncrnaprognosticsignatureassociatedwithimmuneinfiltrationandtumourmutationburdeninbreastcancer
AT zhengxin lncrnaprognosticsignatureassociatedwithimmuneinfiltrationandtumourmutationburdeninbreastcancer
AT wugang lncrnaprognosticsignatureassociatedwithimmuneinfiltrationandtumourmutationburdeninbreastcancer
AT zhangliling lncrnaprognosticsignatureassociatedwithimmuneinfiltrationandtumourmutationburdeninbreastcancer